Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Omigapil (Primary)
- Indications Congenital disorders; Muscular dystrophies
- Focus Pharmacokinetics
- Acronyms CALLISTO
- Sponsors Santhera Pharmaceuticals
- 29 Jan 2018 According to a Santhera Pharmaceuticals media release, the announcement of top line results is planned for early Q2 2018.
- 29 Jan 2018 Status changed from active, no longer recruiting to completed, according to a Santhera Pharmaceuticals media release.
- 29 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 15 Dec 2017.